Lophora, a Danish biotech advancing next-generation psychedelic therapies, announced the first subjects have been dosed in its Phase 1 clinical trial of LPH-5, a novel serotonergic compound targeting central nervous system disorders. The trial, conducted by Biotrial in Rennes, France, is evaluating safety, tolerability, pharmacokinetics, and pharmacodynamics of both single and multiple ascending doses in healthy volunteers.
LPH-5 is engineered for targeted serotonin receptor engagement and designed to provide therapeutic benefits without the hallucinogenic effects commonly associated with traditional psychedelics. A preliminary data review is scheduled for June 17, 2025, with topline results expected in Q4. Company executives described the milestone as a major validation of years of research and a first step toward addressing treatment-resistant depression and other neuropsychiatric conditions.
To view the full press release, visit https://ibn.fm/iyxjr
About Lophora ApS
Lophora is a clinical-stage CNS drug discovery company developing novel, next-generation, rapid-acting medicines to treat neurological and psychiatric disorders, such as depressive, anxiety, eating, and mood disorders, PTSD, and substance use disorders.
The company has identified and patented a new class of proprietary ligands. The lead compound LPH-5 is a highly selective small-molecule agonist of the Serotonin 5-HT2AR and exhibits robust CNS exposure, target engagement and efficacy in animal models of depression. LPH-5 has now entered Phase I trials.
After being spun out from University of Copenhagen Lophora has been funded by BII (Novo Nordisk Foundation), Venture Funds, family offices and experienced biotech investors.
For more information, visit the company’s website at https://www.lophora.com/
About InvestorWire
InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer
InvestorWire
Austin, Texas
www.InvestorWire.com
512.354.7000 Office
[email protected]
InvestorWire is powered by IBN